MOTS-C (40 mg Vial) Dosage Protocol

Supply calculations based on the displayed 8–16-week daily example; actual laboratory requirements depend on the research design.

• Peptide Vials (MOTS-C, 40 mg each):
  • 8 weeks: approximately 1 vial required
  • 12 weeks: approximately 2 vials required
  • 16 weeks: approximately 3 vials required
• Insulin Syringes (U‑100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
• Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • 8 weeks (1 vial): 3 mL — 1 bottle required (10 mL each)
  • 12 weeks (2 vials): 6 mL — 1 bottle required (10 mL each)
  • 16 weeks (3 vials): 9 mL — 1 bottle required (10 mL each)
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs — 2 boxes required (100 swabs each)
  • 12 weeks: 168 swabs — 2 boxes required (100 swabs each)
  • 16 weeks: 224 swabs — 3 boxes required (100 swabs each)

MOTS-C 40 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

• Reconstitute: Add 3.0 mL bacteriostatic water → ~13.33 mg/mL concentration.
• Displayed calculation range: 200–1,000 mcg per administration; these community-reported rows are not a validated clinical regimen.
• Easy measuring: At 13.33 mg/mL, 1 unit = 0.01 mL ≈ 133.3 mcg on a U‑100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F) or below; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); follow documented, formulation-specific discard guidance.

MOTS-C is a mitochondrial-derived peptide studied in cellular, animal, and human observational or exercise settings.^[1][3][4][6] Published human research has not established the injected community schedule shown below, so the table is presented only to make the 40 mg vial concentration and syringe-volume arithmetic transparent.

A 40 mg vial contains 40,000 mcg of MOTS-C. Adding 3.0 mL produces 13,333 mcg/mL. Because a U-100 syringe has 100 volume markings per mL, each unit equals 0.01 mL and contains about 133.3 mcg at this concentration. These are fixed mathematical conversions, not proof of an appropriate dose.

• 200 mcg: 0.015 mL, or 1.5 U-100 units.
• 400 mcg: 0.030 mL, or 3 units.
• 500 mcg: 0.0375 mL, or 3.75 units.
• 600 mcg: 0.045 mL, or 4.5 units.
• 800 mcg: 0.060 mL, or 6 units.
• 1,000 mcg: 0.075 mL, or 7.5 units.

Vial strength changes concentration, syringe markings, and nominal yield; it does not establish a different biological dosage range. At 3.0 mL, this 40 mg vial is four times as concentrated as a 10 mg vial mixed with the same volume. The vial contains a nominal 200 amounts at 200 mcg, 100 at 400 mcg, 80 at 500 mcg, 50 at 800 mcg, or 40 at 1,000 mcg. Nominal yield does not account for handling loss and must not be treated as a storage-life estimate.

Very small volumes can fall between syringe markings. A calculated 1.5-unit or 3.75-unit volume may be difficult to measure accurately with some devices. Confirm the actual syringe scale, never confuse U-100 volume markings with peptide international units, and independently verify the vial mass, final volume, concentration, and conversion before laboratory use.

Current human evidence does not establish a validated MOTS-C injection dosage, titration schedule, route, or treatment duration. Human studies have measured naturally circulating MOTS-C, metabolic associations, and responses to acute or repeated exercise.^[4][6][7][8] Those study designs do not test the community-reported injection rows displayed on this page and cannot be converted into a clinical dosing recommendation.

The distinction matters for a MOTS-C 40 mg reconstitution protocol: the arithmetic can be exact even when the underlying injected regimen lacks human validation. The table therefore shows how specified microgram amounts translate into mL and U-100 markings, while the evidence summary separately explains what researchers have and have not studied.

MOTS-C research includes studies of exercise biology rather than injected dosing. A 2021 study reported MOTS-c as an exercise-induced mitochondrial signal associated with physical capacity in humans, while later work examined circulating responses to acute endurance exercise.^[3][4] A 2024 human study further evaluated circulating MOTS-c in relation to exercise, and a systematic review summarized associations reported across human studies.^[6][7]

These findings help explain why terms such as MOTS-C peptide, metabolic health, insulin sensitivity, exercise performance, and healthy aging appear in the research literature. They do not determine how much exogenous MOTS-C should be injected or whether a 40 mg vial is suitable for a particular use.

MOTS-C is encoded within mitochondrial DNA and functions as a mitochondrial-derived signaling peptide. Foundational laboratory research linked MOTS-C with metabolic homeostasis and AMPK-related energy signaling.^[1] Additional work reported that metabolic stress can promote nuclear translocation and adaptive gene-expression responses.^[2] Reviews describe this mitochondria-to-nucleus signaling framework and the questions it raises for metabolism, aging, and disease research.^[5]

Other preclinical investigations have explored pancreatic islet senescence, autoimmune diabetes models, adipose-tissue homeostasis, bone metabolism, cardiovascular biology, and skeletal muscle.^{[9][10][11][12][13][14]} These subjects are mechanistic or preclinical research areas. They are not evidence that a MOTS-C 40 mg vial, a specific injection amount, or the displayed community schedule produces a clinical benefit.

MOTS-C is not an FDA-approved drug, and no established human injection regimen appears in the published evidence summarized here. The FDA has identified MOTS-C among bulk substances that may present significant safety risks, including concerns associated with immunogenicity and insufficient safety information.^[15] Unknowns include formulation quality, sterility, pharmacokinetics, dose-response behavior, interactions, adverse events, and long-term effects.

Laboratory handling does not remove those uncertainties. Use validated sterile technique, keep research records, and place used needles and syringes directly into an appropriate sharps container according to local requirements.^[16]

Before mixing, keep the sealed lyophilized vial dry, protected from light, and at the temperature stated on its product label. After reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F), protect from light, avoid vigorous shaking, and minimize repeated temperature cycling. Follow formulation-specific supplier or laboratory stability documentation for any discard date. The 40 mg strength and 3.0 mL final volume cannot establish a universal beyond-use period.

To reconstitute MOTS-C accurately, confirm the MOTS-C vial mass and intended final volume before drawing bac water. This 40 mg vial uses 3.0 mL, but a different vial strength and water volume creates a different concentration. A peptide reconstitution calculator or MOTS-C dose calculator is only as accurate as those inputs. Reconstitution math should always be checked in both directions: milligrams per mL and micrograms per U-100 unit.

This step-by-step reconstitution check keeps the MOTS-C protocol calculation separate from biological dose selection:

• Confirm vial mass: 40 mg equals 40,000 mcg per vial.
• Confirm final volume: 3.0 mL of bacteriostatic water is the calculation basis.
• Calculate concentration: 40 mg ÷ 3.0 mL = 13.33 mg/mL.
• Calculate syringe content: 0.01 mL per U-100 unit × 13.33 mg/mL = about 133.3 mcg per unit.
• Recheck the requested amount: divide the specified microgram amount by 133.3 mcg per unit.

Community pages sometimes describe a MOTS-C cycle, weekly dosing, or a number of times per week. Those labels do not create human dosage evidence. This page does not validate such claims; it provides transparent MOTS-C reconstitution and MOTS-C dosage math while the human-evidence limits remain explicit.

How much bacteriostatic water is used in this MOTS-C 40 mg chart?

The chart uses 3.0 mL, producing about 13.33 mg/mL. A different final volume changes every syringe conversion and must be recalculated.

How many mcg are in one U-100 unit?

At 40 mg in 3.0 mL, one U-100 unit equals 0.01 mL and contains approximately 133.3 mcg.

Does a 40 mg vial require a higher MOTS-C dosage?

No. Vial strength determines total material and concentration after mixing. It does not establish the amount per administration.

Is the displayed schedule clinically validated?

No. It is labeled Community-reported use and is included to show calculation relationships. Published human studies have not validated this injected schedule.

Can nominal vial yield determine a discard date?

No. Mathematical yield and stability are different questions. Follow product-specific storage and stability documentation.

This MOTS-C 40 mg dosage protocol is an educational calculation reference. It does not provide medical advice, establish a standard of care, or recommend human consumption. Human observational and exercise findings, preclinical mechanisms, community-reported schedules, and vial-conversion arithmetic are presented as separate evidence categories so that one is not mistaken for another.

• 1
  Cell Metabolism (2015) — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Lee C, Zeng J, Drew BG, et al.)

  View Source
• 2
  Cell Metabolism (2018) — The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress (Kim KH, Son JM, Benayoun BA, et al.)

  View Source
• 3
  Nature Communications (2021) — MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis (Reynolds JC, Lai RW, Woodhead JST, et al.)

  View Source
• 4
  Metabolites (2021) — Acute endurance exercise modulates circulating MOTS-c levels in humans

  View Source
• 5
  Journal of Translational Medicine (2023) — Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging (Wan W, Zhang L, Lin Y, et al.)

  View Source
• 6
  Systematic Review and Meta-analysis (2024) — Human circulating MOTS-c concentrations and metabolic health outcomes

  View Source
• 7
  Human Exercise Study (2024) — Chronic endurance training and circulating MOTS-c levels in athletes

  View Source
• 8
  Human Metabolic Study (2019) — Circulating MOTS-c in women with polycystic ovary syndrome and relationships with insulin and lipid measures

  View Source
• 9
  Experimental & Molecular Medicine (2025) — Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes (Kong BS, Lee H, L’Yi S, et al.)

  View Source
• 10
  Cell Reports Medicine (2021) — MOTS-c and immune-metabolic signaling in autoimmune diabetes models

  View Source
• 11
  Journal of Molecular Medicine (2019) — MOTS-c regulates adipose homeostasis in an ovariectomy-induced metabolic dysfunction model

  View Source
• 12
  Frontiers in Physiology (2023) — Role of MOTS-c in the regulation of bone metabolism

  View Source
• 13
  Cardiovascular Research Review (2023) — Mitochondrial-derived peptides, including MOTS-c, in cardiovascular biology

  View Source
• 14
  Skeletal Muscle Research (2026) — MOTS-c and muscle bioenergetics in a preclinical model

  View Source
• 15
  U.S. Food and Drug Administration (2026) — Safety Risks Associated with Certain Bulk Drug Substances: MOTS-C technical review

  View Source
• 16
  MedlinePlus Medical Encyclopedia — Subcutaneous injection and sharps-disposal guidance

  View Source

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.